Servier
22 Rue Garnier
Neuilly Sur Seine
92200
France
Website: http://www.servier.com/
Email: webmaster@servier.com
188 articles about Servier
-
UPDATED: Takeda Pharma and Shire Come Back to the Negotiating Table and Offer is Set at $64 Billion
4/24/2018
Takeda Pharmaceutical has come back with an improved bid for Shire, making it the fifth round of talks. -
Sanofi has agreed to sell its generics division, Zentiva, to Advent International. The deal is expected to wrap by the end of this year.
-
Only a couple weeks after Takeda Pharmaceuticals announced it was interested in buying Shire, Shire sells its oncology business to France’s Servier for $2.4 billion.
-
Cellectis has found some sure financial footing that will support its efforts through the remainder of the year. The company secured $163.7 million in an initial public offering to develop CART-T products.
-
Taiho Oncology and Servier Present LONSUR mCRC Data at ASCO 2018 Gastrointestinal Cancers Symposium
1/22/2018
A phase I multicenter, open-label study examined the maximum tolerated dose of a LONSURF and oxaliplatin combination in patients with mCRC.
-
Servier and Treventis Begin Strategic Research Partnership in Neurodegenerative Diseases
1/4/2018
This therapeutic strategy aims to provide patients with a drug that slows the progression of pathology in the brain, thereby minimizing functional decline through a disease-modifying mechanism.
-
Preliminary Data From Servier and Pfizer’s UCART19 Product Candidate Shows High Complete Remission Rate Across Two Phase I Adult and Pediatric Acute Lymphoblastic Leukemia Trials
12/13/2017
These first-in-human data demonstrated the safety and tolerability of UCART19, resulting in an 83% complete remission rate across the adult and pediatric patient population.
-
Vernalis and Servier Achieve Research Milestone
12/7/2017
Vernalis will receive a payment of EUR 1.0m from Servier in recognition of this achievement.
-
Servier and Pfizer Announce Preliminary Results of the First-in-Human Trials of UCART19 Will Be Presented at the 59th ASH Annual Meeting
11/2/2017
Results from the CALM (UCART19 in Advanced Lymphoid Malignancies) study will be shared as an oral presentation by Reuben Benjamin, principal investigator and consultant hematologist at King’s College Hospital, United Kingdom, on December 11 at 7.15 pm (EST).
-
Servier CDMO Expands Preparative Chromatography Platform at Normandy Site To Support Market Need
10/19/2017
Servier CDMO today announced that the company has invested &7.5M in intensified technology including continuous chromatography with SMB and SFC with solvent recycling of up to 90% to lower environmental impact.
-
GeNeuro And Servier Announce Six-Month Results From CHANGE-MS Phase IIb Study In Multiple Sclerosis
8/28/2017
-
Philogen S.p.A. Announces Research Collaboration With Servier n The Field Of DNA-Encoded Chemistry
8/25/2017
-
Servier Licenses GLPG1972 In Osteoarthritis From Galapagos
7/28/2017
-
Servier Licenses GLPG1972 In Osteoarthritis From Galapagos
7/28/2017
-
Servier And TRANSGENE Have Become Partners To Apply Viral Vectorization Technology To The Engineering Of Allogenic CAR-T
6/29/2017
-
Servier And ILTOO Pharma Sign A License Option Agreement For The Clinical Development And Commercialization Of Low-Dose Interleukin-2 For The Treatment Of Autoimmune Diseases
5/31/2017
-
Servier And miRagen Extend Collaboration For The Research, Development And Commercialization Of Microrna-Targeting Therapeutics
5/3/2017
-
Servier And Vernalis PLC Announce Achievement Of 3 Milestones In Their Oncology Drug Discovery Collaboration
4/27/2017
-
Servier And CTI BioPharma Expand License And Collaboration Agreement To Develop And Commercialize PIXUVRI
4/25/2017
-
Servier And Pfizer Announce FDA Clearance Of IND Application For UCART19 In Adult Relapsed/Refractory Acute Lymphoblastic Leukemia
3/9/2017